中国医学创新2025，Vol.22Issue(25)：40-44,5.DOI:10.3969/j.issn.1674-4985.2025.25.010
奈达铂与紫杉醇(白蛋白结合型)化疗同步IMRT在颈段及胸上段食管癌中的疗效
Efficacy of Nedaplatin and Paclitaxel(Albumin-bound Type)Chemotherapy Combined with Concurrent IMRT in Cervical and Upper Thoracic Esophageal Cancer
毛润芝1
作者信息
- 1. 泉州市第一医院放射治疗科 福建 泉州 362000
- 折叠
摘要
Abstract
Objective:To analyze the effect of Nedaplatin and Paclitaxel(Albumin-bound Type)chemotherapy combined with concurrent intensity-modulated radiotherapy(IMRT)in patients with cervical and upper thoracic esophageal cancer.Method:Sixty patients with cervical and upper thoracic esophageal cancer from Quanzhou First Hospital from January 2021 to June 2023 were selected as the research subjects.They were randomly divided into two groups based on a random number table method,with 30 patients in each group.The control group received IMRT,while the study group received Nedaplatin and Paclitaxel(Albumin-bound Type)chemotherapy combined with concurrent IMRT treatment.The efficacy of two different treatment regimens and the differences in serum tumor marker levels before and after treatment,as well as the incidence of adverse reactions during treatment and survival of the two groups were observed.Result:Compared with the control group,the effective rate and disease control rate of the study group were higher,the expression levels of serum tumor markers one month after treatment in the study group were lower than those in the control group(P<0.05).There were no statistically significant differences in the incidences of adverse reactions between the two groups(P>0.05).The 1-year survival rate of the study group,the Karnofsky performance status(KPS)score at one-year follow-up of the surviving patients in the study group was higher than that in the control group(P<0.05).Conclusion:The treatment regimen of Nedaplatin and Paclitaxel(Albumin-bound Type)chemotherapy combined with concurrent IMRT can help improve the clinical efficacy of patients with cervical and upper thoracic esophageal cancer,reduce the expression levels of serum tumor markers,and help increase the 1-year survival rate of patients.关键词
紫杉醇(白蛋白结合型)食管癌/适形调强放射治疗/肿瘤标志物Key words
Paclitaxel(Albumin-bound Type)/Esophageal cancer/Intensity modulated radiation therapy Tumor markers引用本文复制引用
毛润芝..奈达铂与紫杉醇(白蛋白结合型)化疗同步IMRT在颈段及胸上段食管癌中的疗效[J].中国医学创新,2025,22(25):40-44,5.
